Cover Image
Market Research Report
Product code
917495

Market Spotlight: Obesity

Published: | Datamonitor Healthcare | 55 Pages | Delivery time: 1-2 business days

Price

Back to Top
Market Spotlight: Obesity
Published: June 17, 2021
Datamonitor Healthcare
Content info: 55 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 681.3 million prevalent cases of obesity in adults (aged 20+ years) worldwide, and expects that number to increase to 762.9 million prevalent cases by 2026.

In the same year, Datamonitor Healthcare estimates that there were 126.6 million prevalent cases of obesity in children and adolescents (aged 5-19 years) worldwide, and expects that number to increase to 134.0 million prevalent cases by 2026.

Prevalence proportions are highest in Northern America and lowest in Asia. The approved drugs in the obesity space target gastric lipase, dopamine, norepinephrine (noradrenaline), dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, GABA-A receptor, and glucagon-like peptide-1 (GLP-1) receptor. The majority of marketed drugs are administered via the oral route, with two products being available in a subcutaneous formulation.

The largest proportion of industry-sponsored drugs in active clinical development for obesity are in Phase I, with only one drug in Phase III.

Therapies in development for obesity focus on a wide variety of targets, with the subcutaneous route being the most common method of delivery.

High-impact upcoming events for drugs in the obesity space comprise a decentralized EU approval and an estimated EU patent expiration for Qsymia, an expected supplemental CHMP opinion for Ozempic, and topline Phase III trial results for tirzepatide.

The overall likelihood of approval of a Phase I obesity asset is 2.5%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 8.5 years from Phase I to approval, compared to 9.6 years in the overall metabolic space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for obesity have been in the early and midphases of development, with 66% of trials in Phase I-II, and 34% in Phase III-IV.

The US has a substantial lead in the number of obesity clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the obesity space is dominated by completed trials. Novo Nordisk has the highest number of completed clinical trials for obesity, with 85 trials.

Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca

Table of Contents
Product Code: DMKC0199735

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Medications
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Ozempic for Obesity (February 10, 2021)
  • Tesomet for Obesity (November 23, 2020)
  • AM833 for Obesity (June 18, 2020)
  • Ozempic for Obesity (June 12, 2020)
  • Ozempic for Obesity (June 4, 2020)
  • Ozempic for Obesity (May 13, 2020)
  • Tesomet for Obesity (April 22, 2020)
  • Efpeglenatide for Obesity (December 10, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Wegovy Is Novo Nordisk's GLP-1 Agonist In A New Guise For Obesity
  • Obesity Drug Imcivree Among Eight New Products To Win EMA Nod
  • EMA Recommends Label Extension Of Saxenda For Obesity
  • Five New EU Filings Leave Starting Blocks at EMA
  • EMA Reviews Amfepramone Medicines
  • Review Vouchers: Danyelza, Imcivree Earn; Novo Nordisk Spends
  • Rhythm's Setmelanotide Loses Fast-Track Status In Europe
  • MAAs Under Review/Rhythm Files Setmelanotide

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Piramal Snaps Up Peptide API Specialist Hemmo
  • Boehringer Ingelheim, Gubra Enter Third Obesity Deal
  • Tonix Obtains U. Of Geneva Oxytocin Technology
  • Senda Teams With Nestle Nutritional Health For Metabolic Conditions
  • CMS Pays $35m For China Rights To Gelesis Obesity Therapy

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of obesity in adults, 2017-26
  • Figure 2: Overview of pipeline drugs for obesity in the US
  • Figure 3: Pipeline drugs for obesity, by company
  • Figure 4: Pipeline drugs for obesity, by drug type
  • Figure 5: Pipeline drugs for obesity, by classification
  • Figure 6: Ozempic for Obesity (February 10, 2021): Phase IIIa - STEP 1 (Weight Loss)
  • Figure 7: Tesomet for Obesity (November 23, 2020): Phase IIa - Hypothalamic Obesity (Denmark)
  • Figure 8: AM833 for Obesity (June 18, 2020): Phase I - w/Semaglutide
  • Figure 9: AM833 for Obesity (June 18, 2020): Phase II - 4433
  • Figure 10: Ozempic for Obesity (June 12, 2020): Phase IIIa - STEP 2 (Overweight/obese diabetics), Phase IIIa - STEP 3 (Maximizing Weight Loss)
  • Figure 11: Ozempic for Obesity (June 4, 2020): Phase IIIa - STEP 1 (Weight Loss)
  • Figure 12: Ozempic for Obesity (May 13, 2020): Phase IIIa - STEP 4 (Maintained Weight Loss)
  • Figure 13: Tesomet for Obesity (April 22, 2020): Phase IIa - Hypothalamic Obesity (Denmark)
  • Figure 14: Key upcoming events in obesity
  • Figure 15: Probability of success in the obesity pipeline
  • Figure 16: Clinical trials in obesity
  • Figure 17: Top 10 drugs for clinical trials in obesity
  • Figure 18: Top 10 companies for clinical trials in obesity
  • Figure 19: Trial locations in obesity
  • Figure 20: Obesity trials status
  • Figure 21: Obesity trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of obesity in adults, 2017-26
  • Table 2: Prevalent cases of morbid obesity in adults, 2017-26
  • Table 3: Prevalent cases of obesity in children and adolescents, 2017-26
  • Table 4: Prevalence proportions of obesity and morbid obesity, 2017
  • Table 5: Marketed drugs for obesity
  • Table 6: Pipeline drugs for obesity in the US
  • Table 7: Ozempic for Obesity (February 10, 2021)
  • Table 8: Tesomet for Obesity (November 23, 2020)
  • Table 9: AM833 for Obesity (June 18, 2020)
  • Table 10: Ozempic for Obesity (June 12, 2020)
  • Table 11: Ozempic for Obesity (June 4, 2020)
  • Table 12: Ozempic for Obesity (May 13, 2020)
  • Table 13: Tesomet for Obesity (April 22, 2020)
  • Table 14: Efpeglenatide for Obesity (December 10, 2019)